



## PRESS RELEASE

May 2, 2022

# CombiGene strengthens its project management capabilities with Alvar Grönberg as Senior Project Manager

**STOCKHOLM — On May 2, 2022, CombiGene ("CombiGene", "The Company") announced that Alvar Grönberg will join the Company on May 2, 2022, when he takes up the position of Senior Project Manager.**

Alvar Grönberg is a Doctor of Medical Science, Karolinska Institutet, Stockholm, and has extensive experience in several disease areas including metabolic diseases and rare diseases. Alvar's experience ranges from early preclinical development to clinical trials from his work in academia and industry. He has worked at the National Cancer Institute, USA, Karolinska Institutet, Pharmacia/Biovitrum and in recent years has been active in biotech companies such as Lipopeptide AB/Pergamum AB and NeuroVive Pharmaceutical AB/Abliva AB.

"I am thrilled to join CombiGene at this very exciting stage in the company's development", said Alvar Grönberg. "Gene therapy holds a fantastic potential, and I am really looking forward to be part of this rapidly evolving field within the pharmaceutical industry."

"One of CombiGene's ambitions for 2022 is to expand our project portfolio with new and promising gene therapy candidates. Alvar Grönberg will be instrumental for the future development as CombiGene takes the next steps in the company's development," said Jan Nilsson, CombiGene CEO.

### About CombiGene AB

CombiGene's vision is to offer patients affected by severe life-changing diseases opportunities for a better life through innovative gene therapies. CombiGene's business concept is to develop effective gene therapies for serious diseases that today lack adequate treatment methods. Research assets are taken in from a network of external researchers and developed further up to preclinical/clinical concept verification. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while CombiGene may drive the development and commercialization in-house for medicines aimed at limited patient populations.

The Company has signed an exclusive collaboration and licensing agreement for CombiGene's CG01 project with Spark Therapeutics.

The company is public and listed on the Nasdaq First North Growth Market and the company's Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99, [info@fnca.se](mailto:info@fnca.se).

### For more information:

*CombiGene AB (publ)*

Jan Nilsson, CEO

Tel: +46 (0)704 66 31 63

[jan.nilsson@combigene.com](mailto:jan.nilsson@combigene.com)

Bert Junno, Chairman of the Board

Tel: +46(0) 70 7 77 22 09

[bert.junno@combigene.com](mailto:bert.junno@combigene.com)

Please read "Ingeneious", a newsletter from CombiGene which contains general news and information that is judged not to have a significant effect on the share price. INGENEIOUS and press releases are available at [www.combigene.com](http://www.combigene.com)